WSAN FRANCISCO—Darolutamide, a structurally unique androgen receptor antagonist, prolongs metastasis-free survival (MFS) and decreases the risk of pain progression in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), without adversely affecting quality of life, according to study findings presented at the 2019 Genitourinary Cancers Symposium and published concurrently in The New England Journal of Medicine. “This…
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.
Please login or register first to view this content.
